Schultz 2004.

Study characteristics
Methods	Study design: randomised, double‐blind, placebo‐controlled trial Setting: University of Regensburg (Regensburg, Germany)
Participants	Inclusion: mild‐to‐moderate CD (CDAI 150‐300) Exclusion: none listed Age: not reported Sex: not reported Number randomised (n = 11): 5 (Group 1); 6 (Group 2)
Interventions	Group 1: one week of corticosteroids and antibiotics (ciprofloxacin 500 mg bid, metronidazole 250 mg tid), followed by 2 x 109 CFU/day of Lactobacillus rhamnosus strain GG (CAG Functional Foods, Omaha, NE) Group 2: one week of corticosteroids and antibiotics, followed by placebo
Outcomes	Duration of follow‐up: 24 weeks Primary outcome: sustained remission Secondary outcomes 1. Remission 2. Relapse 3. CDAI 4. CRP 5. Tolerability 5. SIde effects
Notes	Funding source: partly funded by Deutsche Morbus Crohn und Colitis ulcerosa Vereinigung e.V. (DCCV) Conflicts of interest: none declared
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	There were no details on random sequence generation and no response to email enquiry.
Allocation concealment (selection bias)	Unclear risk	There were no details on allocation concealment and no response to email enquiry.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	There were no details on the methods of blinding and no response to email.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	There were no details on whether outcome assessment was blinded and no response to email.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rates appeared to be low, and balanced, and all attrition was reported.
Selective reporting (reporting bias)	Low risk	The trial registration/protocol was not available, although the intended outcomes specified in the methods were reported and these were as expected.
Other bias	Low risk	The groups appeared to be balanced.